Skip to content

Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy

Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02763878
Enrollment
832
Registered
2016-05-05
Start date
2016-09-30
Completion date
2020-12-31
Last updated
2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition Disorders, Postoperative Complications

Keywords

Uncut Roux-en-Y, Billroth II anastomosis, Distal gastric cancer, Nutrition status, Postoperative complications

Brief summary

The investigators intend to conduct multi-center randomized controlled study to find if Uncut Roux-en-Y anastomosis to the distal gastric cancer patients after radical D2 can reduce the long-term complications, affect the quality of life, and improve the prognosis, comparing to Billroth II anastomosis.

Detailed description

Gastric cancer is still one of the most common malignant tumors, and gastric antrum cancer is still common. Radical surgery is the only way to treat gastric antrum cancer, surgical procedures and reconstruction are closely related with the prognosis and quality of life, the choice is crucial. Gastrojejunostomy after distal gastrectomy may affect the quality of radical surgery, and postoperative diet, nutritional status and quality of life. More and more centers tend to choose Billroth II anastomosis, but patients prone to have a variety of complications, including reflux gastritis and bile reflux, malnutrition, seriously affecting the quality of life and so on. According to preliminary pilot study found that, uncut Roux-en-Y anastomosis way can keep the continuity of nerve-muscle function of the reconstruction of digestive tract, and closes the input in order to reduce the incidence of reflux, for improving the nutritional status and reducing complications and improve quality of life. Therefore, the investigators intend to conduct multi-center randomized controlled study to find if Uncut Roux-en-Y anastomosis to the distal gastric cancer patients after radical D2 can reduce the long-term complications, affect the quality of life, and improve the prognosis.

Interventions

PROCEDUREUncut Roux-en-Y anastomosis

Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.

Typical Billroth II anastomosis would be made after the Distal gastrectomy.

Sponsors

Sixth Affiliated Hospital, Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. pathological diagnosed as the gastric carcinoma, the possibility of removal by the surgeon and imaging physician assessment. 2. no previous history of other malignancies combined. 3. patients have signed informed consent; 4. aged 18 to 80 years old, male or female patients; 5. cardiopulmonary, liver and kidney function was normal, ECOG physical status score of 0 to 1 (see Appendix); 6. the clinician determine the patient does not need emergency surgery;

Exclusion criteria

1. pregnant or lactating women; 2. the liver, lung, bone, and other distant metastasis; 3. supraclavicular lymph nodes, pelvic or ovarian species, peritoneal dissemination, etc; 4. a large number of ascites, cachexia; 5. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension merger, diabetes patients; 6. or mental illness; 7. 4 weeks prior to enrollment participated or are participating in other clinical trials of patients; 8. had undergone surgery, and its influence has not been eliminated in the patient; 9. of the stomach or esophagus history of malignancy, including stromal tumor, sarcoma, lymphoma, carcinoid; 10. patients with active infection (infection causing fever above 38 ℃); 11. patients with poor compliance or researchers consider poor patient compliance; 12. There are other clinical researchers believe that the laboratory the patient should not participate in the trial.

Design outcomes

Primary

MeasureTime frame
Number of participants with treatment-related gastrointestinal and gastroesophageal reflux as assessed by The Los Angeles and Savary-Miller systems for grading esophagitis0-5 years

Countries

China

Contacts

Primary ContactJun-Sheng Peng, PH.D
chensh47@mail.sysu.edu.cn+862038254020
Backup ContactShi Chen, PH.D
cscp@163.com+862038254092

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026